Sarepta Therapeutics Inc. (Sarepta), formerly AVI BioPharma, Inc., is a biopharmaceutical company focused on the discovery and development of ribonucleic acid (RNA)-based therapeutics for the treatment of rare and infectious diseases. The Company has classified its drug development programs as Duchenne Muscular Dystrophy (DMD) and Infectious Disease Programs. The Company’s Duchenne muscular dystrophy (DMD) is primarily focused on its lead product candidate, Eteplirsen. The Company has completed a Phase IIb clinical trial for Eteplirsen. The Company, under its infectious disease programs, is primarily focused on development of a drug candidate for the Marburg hemorrhagic fever virus. The Company’s infectious disease programs is largely funded and supported by the U.S. Department of Defense (DoD).